feedback

Course Director

Eileen M. O'Reilly, MD
Eileen M. O'Reilly, MD

David M. Rubenstein Center for Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, New York

Faculty

Andrea Wang-Gillam
Andrea Wang-Gillam, MD, PhD

Washington University in St. Louis
St. Louis, Missouri

Andrew H. Ko
Andrew H. Ko, MD

Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2016-Jul-14
Expiration Date:2017-Jul-13
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

This is a unique learner-directed, case-centric, and patient voice–inclusive learning activity, in which a panel of top experts shares practical guidance for navigating the challenges of managing pancreatic cancer and providing evidence-based, patient-centric care. Going beyond the standard didactic lectures, Dr. Eileen M. O’Reilly uses a series of illustrative case scenarios and engages her colleagues in a stimulating discussion about how to maximize the use of current treatment options for early-stage and advanced pancreatic cancer, what novel strategies are showing promise for this challenging disease, and how to optimally apply the latest evidence to practice. In addition, as a way of integrating the patient voice into the educational experience, results from a survey conducted with assistance from patient advocacy organizations are discussed at relevant points throughout the activity. These findings highlight the perspectives, experiences, and needs of patients with pancreatic cancer and their caregivers related to clinician–patient communication, provision of education and support, shared decision making, and other important topics.

Upon completion of this activity, participants should be better able to:
  • Cite recent efficacy and safety findings from key clinical trials assessing the current and emerging treatment approaches for pancreatic cancer throughout the disease continuum
  • Develop individualized treatment plans for patients with early-stage and advanced pancreatic cancer that reflect optimal, patient-centric selection and sequencing of therapeutic options
  • Manage disease-related complications or adverse events associated with established and emerging therapies for pancreatic cancer
  • Provide appropriate disease- and treatment-related education and guidance to patients with pancreatic cancer to enable them to meaningfully participate in planning and decisions related to their care

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, radiation oncologists, surgical oncologists, and other healthcare professionals involved in the care of patients with pancreatic cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: July 14, 2016 - July 13, 2017
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.

Course Director and Moderator
Eileen M. O'Reilly, MD
Associate Director, Clinical Research
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician and Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Eileen M. O'Reilly, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Aduro Biotech; Array BioPharma; Astellas Pharma US, Inc.; BioAlliance Pharma; Boston Scientific Corporation; Boston Therapeutics, Inc.; Bristol-Myers Squibb; CASI Pharmaceuticals Inc.; Celgene Corporation; Cipla Inc.; Eli Lilly and Company; EMD Serono, Inc.; Gilead; IntegraGen; MedErgy HealthGroup; MedImmune, LLC.; Merrimack Pharmaceuticals, Inc.; Momenta Pharmaceuticals; Novartis Pharmaceuticals Corporation; Onxeo; Pharmacyclics ​LLC; sanofi-aventis U.S. LLC.; Silenseed LTD; Sillajen; and Vicus Therapeutics.
Grant/Research Support from Abbott Laboratories; Amgen Inc.; Bayer Corporation; CASI Pharmaceuticals Inc.; Celgene Corporation; Eli Lilly and Company/ImClone Systems; Exelixis, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Immunomedics, Inc.; Incyte Corporation; Momenta Pharmaceuticals; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; Polaris Pharmaceuticals, Inc.; and Vicus Therapeutics.

Eileen M. O'Reilly, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various systemic treatment options for pancreatic cancer.

Faculty
Andrea Wang-Gillam, MD, PhD
Associate Professor
Clinical Director, Gastrointestinal Oncology Program
Division of Oncology
Washington University in St. Louis
St. Louis, Missouri

Andrea Wang-Gillam, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie; Aduro Biotech, Inc.; BioMed Valley Discoveries, Inc.; ChemoCentryx, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Genentech Inc.; Millennium Pharmaceuticals, Inc., The Takeda Oncology Company; NewLink Genetics; OncoMed Pharmaceuticals, Inc.; Pfizer Inc.; Precision Biologic Inc.; and Verastem, Inc.
Advisory Board for Merrimack Pharmaceuticals, Inc.; NewLink Genetics Corporation; and Pfizer.

Andrea Wang-Gillam, MD, PhD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various systemic treatment options for pancreatic cancer.

Andrew H. Ko, MD
Professor of Clinical Medicine
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Andrew H. Ko, MD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Aduro Biotech, Inc.; Celgene Corporation; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Merck & Co., Inc.; Merrimack Pharmaceuticals, Inc.; and Prism Bio Ltd.
Advisory Board for Aduro Biotech, Inc. (Steering Committee-Unpaid); ARMO Biosciences; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Halozyme, Inc.; Incyte Corporation (Data Safety Monitoring Committee); and Merrimack Pharmaceuticals, Inc.

Andrew H. Ko, MD, does intend to discuss either non–FDA-approved or investigational use for the following products/devices: Various systemic treatment options for pancreatic cancer.

CME Reviewer
Shaina Rozell, MD, MPH
Northwestern University
Chicago, IL

Shaina Rozell, MD, MPH, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education

Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This CME activity has been developed in collaboration with The Lustgarten Foundation.

Support
This activity is supported by educational grants from Celgene Corporation, Merrimack Pharmaceuticals, Inc. and NewLink Genetics.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.